Author: Daikopoulou, Vasiliki; Apostolou, Panagiotis; Mourati, Sofia; Vlachou, Ioanna; Gougousi, Maria; Papasotiriou, Ioannis
Title: Targeting SARS-CoV-2 Polymerase with New Nucleoside Analogues Cord-id: u6j16fgr Document date: 2021_6_7
ID: u6j16fgr
Snippet: Despite the fact that COVID-19 vaccines are already available on the market, there have not been any effective FDA-approved drugs to treat this disease. There are several already known drugs that through drug repositioning have shown an inhibitory activity against SARS-CoV-2 RNA-dependent RNA polymerase. These drugs are included in the family of nucleoside analogues. In our efforts, we synthesized a group of new nucleoside analogues, which are modified at the sugar moiety that is replaced by a q
Document: Despite the fact that COVID-19 vaccines are already available on the market, there have not been any effective FDA-approved drugs to treat this disease. There are several already known drugs that through drug repositioning have shown an inhibitory activity against SARS-CoV-2 RNA-dependent RNA polymerase. These drugs are included in the family of nucleoside analogues. In our efforts, we synthesized a group of new nucleoside analogues, which are modified at the sugar moiety that is replaced by a quinazoline entity. Different nucleobase derivatives are used in order to increase the inhibition. Five new nucleoside analogues were evaluated with in vitro assays for targeting polymerase of SARS-CoV-2.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date